NCT03703596View on ClinicalTrials.gov

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

PHASE2UnknownINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

November 1, 2019

Study Completion Date

November 1, 2020

Conditions
Lung CancerLung Cancer Metastatic
Interventions
DRUG

Anlotinib Hydrochloride

Anlotinib (12mg QD PO d1-14, 21 days per cycle)

DRUG

Docetaxel

Docetaxel (75mg/m2 IV d1, 21 days per cycle)

Trial Locations (10)

Unknown

People's hospital of deyang city, Deyang

Chengdu fifth people's hospital, Chengdu

Sichuan cancer hospital, Chengdu

People's hospital of guangan city, Guangan

The affiliated hospital of southwest medical university, Luzhou

Nanchong central hospital, Nanchong

Neijing second people's hospital, Neijiang

Suning central hospital, Suning

Zigong first people's hospital, Zigong

Zigong fourth people's hospital, Zigong

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Sichuan Cancer Hospital and Research Institute

OTHER